Clinical Issues, Serological issues and Treatment of Chronic Hepatitis C at Two Medical Centers in Bogotá, Colombia
DOI:
https://doi.org/10.22516/25007440.440Keywords:
Gastroenterology, hepatitis C virus, hepatitis C infection risk factors, treatmentAbstract
Introduction: Hepatitis C affects about 170 million people worldwide. The World Health Organization (WHO) has estimated global prevalence at 2%. Overall, about 40% of patients respond to dual therapy treatment for genotype. In Colombia data available for confirm a similar pattern and for describing the clinical characteristics of patients with this infection are scarce.
Methods: Medical records of patients in the Hepatology outpatient service at the Clínica Universitaria Colombia who had been diagnosed with chronic hepatitis C by one of the authors between January 1, 2010 and May 30, 2013 were retrospectively reviewed for clinical characteristics, serological characteristics and treatment responses.
Results: The medical records of 163 patients were evaluated: 62% were female, 38% were male, and their mean age was 58.2 years. The main risk factor for acquiring hepatitis C was a history of transfusions before 1992. This factor was present in 62% of the patients. The decision to start treatment was made for 77 patients (47.2%), but 86 patients (52.8%) did not start treatment. Reasons included advanced age and advanced cirrhosis which together accounted for more than 50% of these patients. Other reasons for not starting treatment were minimal disease (4.7%), minimal sign of disease plus advanced age (10.5%), spontaneous healing (14%), low probability of response (3.3%) and others (14%). Of the 62 patients for whom information about previous or recent treatments was available, 30.6% had sustained virological responses (SVR), 29.0% were classified as relapsers, 8.1% as partial responders, 19.4% had no response, and 12.9% discontinued treatment because of intolerance.
Conclusions: The most frequent antecedent of HCV in the group of patients studied a history of transfusions associated with gynecological surgery before 1992. About half of the patients were diagnosed late. Hepatitis was more likely to have been treated in these patients than in patients in other studies, but the SVR rate was similar to those found in other series. This study opens doors to the realization of other studies to more broadly define the prevalence, risk factors and treatment response variables of this entity in our country.
Downloads
References
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
Averhoff FM, Glass N, Holtzman D, Global burden of hepatitis C: considerations for healthcare providers in the United States, Clin Infect Di 2012; 55(Suppl. 1): S10-5.
Louie K, St Laurent S, Forssen U, Mundy L, Pimenta J. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infectious Diseases 2012; 1286.
Burguete-García A, Conde-González C, Jiménez-Méndez R, Juárez-Díaz Y, Meda-Monzón E, Madrid-Marina V, et al. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Salud Pública de México 2011; 53S7-S12.
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-38.
Lavanchi D. Evolving Epidemiology of Hepatitis C Virus. Clin Microbiol Infect 2011; 17: 107-115.
Aman W, Mousa S, Shiha G, Mousa S. Current status and future directions in the management of chronic hepatitis C. Virology Journal 2012; 957.
Louie, et al. The high comorbidity burden of the hepatitis C virus infected population in the United States, BMC Infectious Diseases 2012; 12: 86.
Informe comportamiento de la hepatitis b y c II trimestre 2011 SIVIGILA II trimestre 2011.
Guías de diagnóstico y tratamiento de hepatitis C. Rev Col Gastroenterol 2012; 27 (Supl. 4).
Horner SM, Gale M Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 2009; 29: 489-98.
Thio CL, Thomas DL. Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology 2010; 138: 1240-3.
Beltrán M, Navas MC, De la Hoz F, Mercedes Muñoz M, Jaramillo S, et al. Hepatitis C virus seroprevalence in multi-transfused patients in Colombia. J Clin Virol 2005; 34(Suppl. 2): S33-38.
Arias Y R, Echeverry S J, Castro M A, Rios M F, Martinez O, frecuencia de genotipos y subtipos de virus de la hepatitis c en pacientes colombianos con infección crónica. Rev Medica Sanitas 2010; 13 (3): 10-19.
Farfan YA, Garzón MA, Rey MH. Prevalencia de hepatitis C por reacción de cadena de la polimerasa (PCR), en donantes de Banco de sangre. Revista Colombiana de Gastroenterología 2007; 22(4): 308-312.
Botero R, Idrovo V, et al. Genotipos de VHC. Revista Colombiana de Gastroenterología 1998; XII: 25-27.
Leonard B. Seeff, Natural History of Chronic Hepatitis C. Hepatology 2002; 36(5).
Oh R, Hustead T. Causes and evaluation of mildly elevated liver transaminase levels. American Family Physician 2011; 84(9): 1003-1008.
Seeff LB. Why is there such difficulty in defining the natural history of hepatitis? Transfusion 2000; 40: 1161-1164.
Paul H. Hayashi, Adrian M. Di Bisceglie, The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis, Med Clin N Am 2005; 89 371-389.
Hugo R. Rosen, Chronic Hepatitis C Infection, N Engl J Med 2011; 364: 2429-38.
Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973.
Vanegas N, Román J, Febles M, Sánchez C, Suárez J, López M, et al. Tratamiento de la infección crónica por el virus de la hepatitis C. Factores predictores de respuesta. Revista Española De Quimioterapia 2011; 24(4): 198-203.
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
Zeuzem Stefan, Andreone Pietro, Pol Stanislas, Lawitz Eric, Diago Moises, Roberts Stuart, et al, Telaprevir for Retreatment of HCV Infection, N Engl J Med 2011; 364: 2417-28.
Bacon R. Bruce, Gordon C Stuart, Lawitz Eric, Marcellin Patrick, Vierling M John, Zeuzem Stefan, Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, N Engl J Med 2011; 364: 1207-17.
Shan Liu, Lauren E. Cipriano, Mark Holodniy, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert, New Protease Inhibitors for the Treatment of Chronic Hepatitis C, A Cost-Effectiveness Analysis, Annals of Internal Medicine 2012; 156: 4.
Bezemer Geert et al. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study, BMC Gastroenterology 2012; 12: 11.
Haider S, Ahmad J. Update of old and emerging therapies in chronic hepatitis C. JPMA. The Journal of The Pakistan Medical Association 2011; 61(12): 1226-1230.
Cisneros-Garza L. Nuevos avances en el manejo de la hepatitis C. Salud Pública de México 2011; 53S52-S60.
T. Jake Liang, Marc G. Ghany, Current and Future Therapies for Hepatitis C Virus Infection, N Engl J Med 2013; 368: 1907-17.
Chao D1, Botwin GJ, Morgan TR. Update on Recently Approved Treatments for Hepatitis C. Curr Treat Options Gastroenterol 2014. [Epub ahead of print].
Hadziyannis SJ, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241-246.
Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133: 665-675.
Lee J, Payette M, Osiecki J. Viral hepatitis: targeted tests and therapies contribute to improved outcomes. MLO: Medical Laboratory Observer 2012; 44(3): 18-20.
Mach T, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Ciećko-Michalska I, et al. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnętrznej 2011; 121(12): 434-439.
Ghany, et al. Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology 2009; 49(4).
Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005; 25: 52-64.
Gebo A Kelly, et al. Role of Liver Biopsy in Management of Chronic Hepatitis C: A Systematic Review. Hepatology 2002; 36(5): 1.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
Abraira García, Luisa, García Sierra, Alberto, Guillán Pavón, Begoña. Otero Antón, Esteban, Suárez López, Francisco. Guía de práctica clínica Hepatitis C. Santiago de Compostela 2009.
McCarthy M, Wilkinson ML. Hepatology. BMJ (Clinical Research Ed.) 2000; 318: 1256-9.
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-I444.
Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K,Welland O Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa -2a and ribavirin. Scan J Gastroenterol 2007; 42(7): 247-255.
Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, et al. The Role of Serum Biomarkers in Predicting Fibrosis Progression in Pediatric and Adult Hepatitis C Virus Chronic Infection, 2011 PLoS ONE 6(8): e23218.
Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288.
Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010; 30: 240.
Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46: 1741.
McHutchison G John, Lawitz J Eric, Shiffman Mitchell, Muir J Andrew, Galler W Greg, McCone Jonathan, Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, N Engl J Med 2009; 361: 580-93.
Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001; 49: 423.
Datz C, Cramp M, Haas T, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999; 44: 563.
Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 10.
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
